leisure time -WSS

leisure time

author：fashion 2025-09-02 08:13:20 - browse：89748

Three Wegovy injection pens in a row — first opinion coverage from STAT — Adobe

Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease, and, as part of that, will study if the treatments will change the amount of alcohol people drink.

This appears to be the first time the company is getting involved in research to see if the booming class of GLP-1 diabetes and obesity drugs can affect substance consumption, a question that academic researchers have been probing but the pharmaceutical industry has so far avoided.

The nine-month study will try three drugs alone and in combinations against placebo. The primary outcome being tested is change in liver scarring, or fibrosis, and one of the secondary outcomes is changes in alcohol consumption. The news of the study was first reported by Bloomberg.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： H5N1 bird flu outbreak: Second human case reported, in Michigan

WSS

How to improve immunocompromised access to mAb treatments

Investigation reveals sickle cell patients pressured into sterilizations

ASCO eve: Let’s set the table for this year's meeting

Readout LOUD podcast: What to know about H5N1 bird flu

Study: Adult vaccinations pay for themselves in societal benefits

Researchers on aging grapple with how to calculate biological age

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Alkermes shareholders re

Shionogi licenses Pompe disease therapy from Maze Therapeutics

Jerome Adams on the need for new antivirals for Covid

Citing H5N1 threat, CDC urges peak flu monitoring this summer

In age of alternative facts, a scholarly course on calling out crap

Making AI in medicine accessible to smaller, and rural hospitals

Walensky prepares to leave CDC — and Congress — behind

Biogen joins immunology wave with $1.15 billion acquisition of HI

hotspot

Study: Adult vaccinations pay for themselves in societal benefits

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

H5N1 bird flu: what we're starting to learn about infection in cows

Medicare says breakthrough device reimbursement rule to come by summer

Study: Adult vaccinations pay for themselves in societal benefits

Bird flu outbreak in cows is latest avian flu curveball

explore

focus

hotspot

Wikipedia